Table 1.

Reported Cases of coexistent pulmonary hemorrhage and venous thromboembolism in patients with AAV

No.	Author	Age/Sex	Involved organ	ANCA	Presentation	Steroid (total dose)	CYC	Other agent	PLEX (N sessions)	AC	IVC filter	Outcome
1	Sousa et al. [7]	48(F)	Renal, ENT	PR3-ANCA	Simultaneous PH and PE	Y(1g)	No	MMF	Y(5)	No	Y	Survived, Recurrent PE, Long term AC
2	Sousa et al. [7]	19(F)	Renal, ENT	PR3-ANCA	Simultaneous PH and multiple PE’s, Upper limb DVT	Y(3g)	Y	No	No	UFH	No	Survived, Short-term AC
3	Sousa et al. [7]	61(M)	Renal, ENT, CNS, Skin	MPO-ANCA	PH 2 weeks after multiple PE’s	Y(3g)	No	Rituximab, IVIG	Y(5)	LMWH	Y	Survived, Pulmonary fibrios, Short term AC
4	Sousa et al. [7]	45(M)	Renal, ENT	PR3-ANCA	PH 1 week before multiple PE’s and Lower limb DVT	Y(3g)	Y	No	No	LMWH	Y	Survived, CKD stage 3, Long term AC
5	Dreyer et al. [8]	31(M)	Renal	PR3-ANCA	PH 1 week after Lower limb DVT and PE	Y(1.5g)	Y	No	Y(5)	UFH	Y	Survived, Short-term AC
6	Our case	14(F)	Renal, Skin	MPO-ANCA	PH 5 days after right lower limbs DVT	Y(3g)	Y	MMF	Y(5)	LMWH	N	Survived, Short-term AC

M, male; F, female; Y, yes; ENT, ear, nose and throat; CNS, central nervous system; PE, pulmonary embolism; PH, pulmonary hemorrhage; DVT, deep vein thrombosis; CYC, cyclophosphamide; MMF, mycophenolate mofetil; IVIG, intravenous immunoglobulin; PLEX, plasmapheresis; UFH, unfractioned heparin; LMWH, low molecular weight heparin; AC, anticoagulant; IVC filter, inferior vena cava filter; CKD, chronic kidney disease